medac Pharma promotional meeting

This promotional meeting is being funded and organised by medac Pharma and is intended for UK Healthcare Professionals only. Prescribing information and Adverse Event Reporting can be found at the bottom of the page 

When, who and why to switch from oral to Subcutaneous methotrexate in Psoriasis.

Wednesday 6 May
18:30 – 19:30

This meeting is taking place between 18:30 – 19.30 on Wednesday 6th May 2026. The webinar hosted by Teena Mackenzie (Nurse Consultant, Royal Berkshire Hospital) and Emma Button (Advanced Nurse Practitioner and Clinical Nurse Specialist, NHS) will cover the topic of When, who and why to switch from oral to Subcutaneous methotrexate in Psoriasis.

Register for this webinar

Click here for Metoject® PEN (methotrexate) prescribing information.

Metoject PEN is indicated for the treatment of active rheumatoid arthritis in adult patients, polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate, moderate to severe psoriasis in adult patients who are candidates for systemic therapy, and severe psoriatic arthritis in adults, and mild to moderate Crohn’s disease either alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines1

  1. medicines.org.uk. Metoject PEN – Summary of Product Characteristics (SmPC) – (emc). [online] Available at: https://www.medicines.org.uk/emc/product/11351/smpc Last Accessed: March 2026.

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard
Adverse event should also be reported to medac drug safety at: drugsafety@medac.de

Patients must be educated and trained in the proper injection technique when self-administering methotrexate. The first injection of Metoject® PEN should be performed under direct medical supervision. Metoject® PEN is injected once weekly.

medacuk D159/04/2026 | April 2026